Shire sells cancer drugs to Servier as Takeda circles

Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical, is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion. As Pascale Davies reports, the deal suggests there is value locked up within Shire's portfolio - despite a dismal share price performance in the past two years.